BioCardia completes revised FDA pre-submission for Helix Catheter
BioCardia reported it has completed a revised Pre-Submission to the FDA's Center for Devices and Radiological Health for approval of its Helix Catheter, which is used for delivering therapeutic and diagnostic agents to the heart. The filing says FDA agreed in May 2026 that there are two pathways to marketing clearance and raised no concerns about Helix safety data or device performance, so the revised submission is a regulatory step toward a possible market clearance.
Key points
- Revised pre-submission completed under the Q-Submission program, reported October 1, 2026.
- FDA met with the company in May 2026 and said there are two pathways for Helix marketing clearance.
- FDA targets an initial acceptance or refusal review within 15 calendar days and written feedback or a meeting within 70 calendar days.
- The company cites clinical data from 15 clinical trials including nearly 500 patients.
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.